Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Overview of attention for article published in The Lancet, July 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 10 news outlets
policy: 3 policy sources
twitter: 32 X users
patent: 3 patents

facebook: 3 Facebook pages
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 535 Mendeley

So far, Altmetric has seen 3 public wall posts from 3 users.

Tom Heston MD, 22 Jul 2017

Related…

UC Davis Neuromuscular Research, 18 Jul 2017

Study published this week in the prestigious British medical journal, The Lancet, suggests promising treatment for some…

The Flanigan Lab at Nationwide Children's Hospital, 18 Jul 2017

We are very pleased to have been a part of the study of ataluren, newly published in The Lancet, that shows evidence for…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.